Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.94 USD | -1.61% | -13.54% | -52.36% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 65% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-52.36% | 2.51B | C+ | ||
+29.38% | 48.16B | B- | ||
-1.02% | 41.73B | B | ||
+43.45% | 41.03B | A | ||
-5.26% | 28.77B | C | ||
+10.17% | 25.59B | B- | ||
-23.19% | 18.96B | B | ||
+8.32% | 12.92B | B+ | ||
+28.77% | 12.03B | C+ | ||
-1.93% | 11.77B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ACAD Stock
- Ratings ACADIA Pharmaceuticals Inc.